Video

Dr. Dimou on Progress Made in ALK+ Lung Cancer Treatment

Anastasios (Tassos) Dimou, MD, discusses the progress made in the treatment of patients with ALK-positive lung cancer.

Anastasios (Tassos) Dimou, MD, a medical oncologist at Mayo Clinic, discusses the progress made in the treatment of patients with ALK-positive lung cancer.

Crizotinib (Xalkori) was the first drug to receive FDA approval for use in this patient population, says Dimou. The most recent advances include the newer-generation TKIs, which have all been compared with crizotinib in the first-line treatment of patients with ALK-positive lung cancer, adds Dimou.

Results from the phase III ALEX trial showed that treatment with alectinib (Alecensa) resulted in improved progression-free survival (PFS). Furthermore, brigatinib (Alunbrig) was compared directly with crizotinib in the first-line treatment of this patient population; this drug also led to improved PFS, says Dimou.

The biggest advances over the past couple of years has been the change in the first-line choices that are available, says Dimou; there has been a shift from crizotinib to the newer-generation TKIs such as alectinib and brigatinib. After these agents, lorlatinib or other agents can be used in subsequent lines of therapy, concludes Dimou.

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD